Neovasc to Report Third Quarter 2021 Financial Results on November 9, 2021
Neovasc Inc. (NASDAQ: NVCN, TSX: NVCN) will report its financial results for the quarter ending September 30, 2021, on November 9, 2021, at 4:30 PM EDT. The announcement will be led by President and CEO Fred Colen, along with CFO Chris Clark, during a conference call. Participants can access the call by phone or via a webcast on Neovasc's investor relations page. Neovasc specializes in medical devices for cardiovascular treatment, with products like the Neovasc Reducer™ and Tiara™, currently under clinical investigation.
- Upcoming financial results announcement may provide insight into company performance.
- Company is a leader in developing minimally invasive cardiovascular devices.
- Neovasc Reducer™ is not commercially available in the U.S., limiting market reach.
VANCOUVER, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on November 9, 2021.
Interested parties may access the conference call by dialing (877)-407-9208 or (201)-493-6784 (International) and reference Conference ID 13723809. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at https://www.neovasc.com/investors/.
A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.617.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
Sean.Leous@icrinc.com
FAQ
When will Neovasc report its financial results for Q3 2021?
Who will be presenting Neovasc's financial results?
How can I access the Neovasc financial results conference call?
What products does Neovasc focus on?
